//

Biogen Idec, Inc.

Posted Mon, 09/14/2009 - 12:20 by Zefu

Biogen Idec, Inc.

14 Cambridge Center
Cambridge, MA 02142
USA
Phone: (617) 679-2000
Fax: (617) 679-2617
Email: idecir@idecpharm.com
Web Site: http://www.idecpharm.com

A. Company Profile

Biogen Idec (NASDAQ: BIIB) was formed from the merger of two of the world's leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation. This combination has resulted in a fusion of complementary strengths in research and development capabilities, manufacturing expertise, and global infrastructure in the area of oncology.

B. Products

Product Pipelines
Product Indication Clinical Status
Avonex (Interferon beta 1a) Glioma Phase II
Galiximab (Anti-CD89 Mab) Non-Hodgkin's B-cell lymphoma Phase III
HSP90 inhibitor Various tumors Phase II
Intron A Various tumors Market
Lumiliximab (Anti-CD23 Mab) Chronic lymphocytic leukemia Phase II
M200 (Volociximab) Various tumors Phase II
Rituxan Chronic lymphocytic leukemia and B cell non-Hodgkin's lymphomas Market
  Melanoma Phase III
  Colorectal cancer Phase II
  Lymphoma, multiple myeloma, and pancreatic cancer Phase I
Zevalin B cell non-Hodgkin's lymphoma Market

1. Avonex

Avonex is an interferon beta (interferon beta-1a), gene delivery product for glioma that is in Phase II clinical trial. Interferon beta gene delivery has exhibited direct and indirect anti-tumor activity and has the potential to treat a broad range of tumors with unmet medical need.

2. Galiximab

Galiximab is an humainized Mab specific for CD23.

3. HSP90 inhibitor

HSP90 inhibitor is a novel small molecule HSP90 inhibitor.

4. Intron A

Intron A (interferon alfa-2b, recombinant) is a leading treatment for various cancers. Intron A is now the leading product in the $2 billion global alpha interferon market.

5. M200

M200 is a chimeric nonoclonal antibody specific for VLA5 (alpha5beta1 integrin).

6. Rituxan

In November 1997, Rituxan (rituximab) became the first monoclonal antibody to be approved by the U.S. Food and Drug Administration for a cancer indication. Rituxan is indicated for the treatment of patients with relapsed or refractory, low grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma, which is a cancer of the lymphatic system.

7. Zevalin (Ibritumomab tiuxetan)

Zevalin is the first approved radioimmunotherapy for the treatment of certain B-cell non-Hodgkin's lymphomas. Zevalin is indicated for the treatment of relapsed or refractory low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL) including patients with rituxan refractory follicular NHL. Radioimmunotherapies are manufactured by linking monoclonal antibodies - engineered in a laboratory to recognize and attach to substances on the surface of certain cells - to radioactive isotopes - in Zevalin's case, the radioisotope yttrium-90.